Full Archive

A New Predictive Model Could Help Doctors Choose the Best Surgery for Mesothelioma Patients

July 16, 2021
Categories: , , , ,

Doctors could soon pick the best surgery for pleural mesothelioma patients because of a new predictive model created by Harvard researchers. There are different types of mesothelioma surgery: one involves removing a lung while the other leaves the lungs. The best surgery for each individual patient depends on the person’s demographics, symptoms, and lab values.…

Immunotherapy Treatment for Mesothelioma Could Become Safer and More Effective

July 9, 2021
Categories: , , ,

Research could help create better and safer immunotherapy treatments for mesothelioma. Immunotherapy is a fast growing and exciting way to treat cancer because it uses the body’s own immune system to treat cancer instead of harmful drugs like chemotherapy.  Immunotherapy can be way more effective than typical treatments, but it can also have very bad…

UNITO-001-A Phase II Study Niraparib Plus Dostarlimab in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)

July 2, 2021
Categories: , , , ,

This is a single arm, prospective, interventional, multicenter phase 2 study of the combination of niraparib and dostarlimab in patients with advanced non-small cell lung cancer (NSCLC) and/or malignant pleural mesothelioma (MPM), and positive for PD-L1 expression (TPS ≥ 1%) and germline or somatic mutations in the DNA homologous recombination repair (HRR) genes.

GPS Vaccine is Effective in Mesothelioma Patients When Paired with Opdivo

July 2, 2021
Categories: , , , , , ,

A new cancer vaccine was found to be effective in mesothelioma patients alongside Opdivo in a new study. It was studied in people whose cancer no longer responded to standard chemotherapy. The phase I clinical trial took place at the Memorial Sloan Kettering Cancer Center and it involved the galinpepimut-S vaccine, or GPS. Data early…

Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma

June 25, 2021
Categories: , , , ,

This phase I trial studies the effect of stereotactic body radiation therapy and immunotherapy in treating patients with mesothelioma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving stereotactic body radiation therapy and immunotherapy may improve the tumors response to the treatment and decrease side-effects.

Vinorelbine Could Soon be Used to Treat Mesothelioma

June 25, 2021
Categories: , , , , ,

Vinorelbine could be a useful second-line treatment for patients with relapsed mesothelioma. A phase II clinical trial examined vinorelbine to see how effective it is in patients who had their pleural mesothelioma progress after platinum chemotherapy treatment. Doctors believe vinorelbine could be another option for patients instead of the standard platinum-based chemotherapy. The study, which…

Pleural Effusion in Mesothelioma Patients May Affect Survival

June 18, 2021
Categories: , , , ,

Pleural effusion may affect mesothelioma survival. Pleural effusion is a buildup of fluid around the lungs that can be caused by multiple illnesses including heart failure, kidney and liver disease, pleural mesothelioma, and other cancers. The only way to treat this condition is to drain the fluid, which makes it easier for patients to breathe.…

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma

June 11, 2021
Categories: , , , ,

Primary Outcome Measures Objective response rate (ORR) [ Time Frame: Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximatively 9 months after the last participant receive first dose. ] Objective response rate (ORR), defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR), derived based…

Adjuvant Radiotherapy Does Not Improve Survival in Pleural Mesothelioma Patients

June 11, 2021
Categories: , , , , ,

Adjuvant radiotherapy might not be the best treatment for mesothelioma sufferers because researchers at Duke and Stanford found that this therapy does not help patients live longer. The researchers analyzed a database of pleural mesothelioma patients at Duke and a national registry of patients. The research looked at the outcomes of patients with radiation after…

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

June 4, 2021
Categories: , , , ,

Primary Outcome Measures Number of Patients with Dose-limiting Toxicities [ Time Frame: Baseline up to 28 Days ] A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by the investigator to be clinically…